- Trials with a EudraCT protocol (77)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
77 result(s) found for: Dna Methylation.
Displaying page 1 of 4.
| EudraCT Number: 2017-002097-38 | Sponsor Protocol Number: ABR62020 | Start Date*: 2018-06-05 |
| Sponsor Name:University Medical Centre Utrecht | ||
| Full Title: SAMe as an epigenetic treatment of depression in people with childhood trauma, a double blind placebo-controlled trial | ||
| Medical condition: Depressive episode in people with childhood trauma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-005086-40 | Sponsor Protocol Number: J1214 | Start Date*: 2014-05-21 | |||||||||||
| Sponsor Name:Sidney kimmel Comprehensive Cancer Center at Johns Hopkins | |||||||||||||
| Full Title: A multi-institutional open label, trial evaluating the efficacy of Gemcitabine and Docetaxel in patients with relapsed or refractory metastatic colorectal adenocarcinoma with methylated CHFR and/or... | |||||||||||||
| Medical condition: relapsed or refractory metastatic colorectal adenocarcinoma with methylation of CHFR and/or microsatellite instability | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-001407-23 | Sponsor Protocol Number: GEICAM/2015-06 | Start Date*: 2017-01-05 | |||||||||||
| Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama) | |||||||||||||
| Full Title: A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast study). | |||||||||||||
| Medical condition: Patients with advanced triple negative breast cancer (TNBC) with BRCA1 and/or BRCA2 promoter methylation assessed in DNA from metastatic lesions and absence of BRCA1 and 2 germline mutations. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-000149-53 | Sponsor Protocol Number: D-STAPH | Start Date*: 2014-05-06 |
| Sponsor Name:Karolinska University Hospital, Huddinge | ||
| Full Title: ’D-STAPH’ Vitamin D supplementation to persistent carriers of MRSA – A double blind, randomised controlled trial | ||
| Medical condition: Persistent MRSA carriers | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-000155-41 | Sponsor Protocol Number: 1 | Start Date*: 2019-01-10 |
| Sponsor Name:Department of Medical and Clinical Genetics, University of Helsinki | ||
| Full Title: The effect of vitamin C on the gene methylation load in patients with TET2 mutations | ||
| Medical condition: germline TET-2 gene mutation | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-006151-20 | Sponsor Protocol Number: D1449L00029 | Start Date*: 2006-08-29 | |||||||||||
| Sponsor Name:University of Erlangen-Nuremberg | |||||||||||||
| Full Title: Quetiapine and the dopaminergic epigenetic control – a pilot study | |||||||||||||
| Medical condition: Patients suffering from schizophrenia (ICD10: F20.x) Healthy controls | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000689-30 | Sponsor Protocol Number: Pem-NSCLC | Start Date*: 2018-08-02 |
| Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie | ||
| Full Title: Expression/DNA methylation of cancer testis antigens may predict response to pembrolizumab in pretreated NSCLC patients | ||
| Medical condition: untreated patients with adenocarcinoma of the lung of advanced stage | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-003296-60 | Sponsor Protocol Number: Oxidise | Start Date*: 2018-04-09 |
| Sponsor Name:University Hospital Tuebingen | ||
| Full Title: Empagliflozin effect on glucose toxicity in type 2 diabetes patients - a randomized, open-label, controlled, parallel group, exploratory study | ||
| Medical condition: Patients with T2DM aged 40 to 70 years (including) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-003977-24 | Sponsor Protocol Number: SGI-110-03 | Start Date*: 2014-03-20 | |||||||||||
| Sponsor Name:Astex Pharmaceuticals Inc | |||||||||||||
| Full Title: A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment with Sorafenib | |||||||||||||
| Medical condition: Advanced Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-023584-17 | Sponsor Protocol Number: RAS-AZIC | Start Date*: 2012-08-31 | |||||||||||
| Sponsor Name:Universität Leipzig | |||||||||||||
| Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent... | |||||||||||||
| Medical condition: acute myeloid leukeamia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-005268-41 | Sponsor Protocol Number: HE5A/15 | Start Date*: 2016-04-25 | |||||||||||
| Sponsor Name:Hellenic Cooperative Oncology Group | |||||||||||||
| Full Title: Phase ΙΙ (window) preoperative study of olaparib with or without cisplatin or no treatment in patients with histologically proven squamous cell carcinoma of the head and neck who are candidates for... | |||||||||||||
| Medical condition: Histologically proven operable squamous cell carcinoma of the head and neck. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004444-31 | Sponsor Protocol Number: KWMP001 | Start Date*: 2015-01-09 |
| Sponsor Name: | ||
| Full Title: Effects and consequences for mother and child from treatment for depression A prospective randomized, placebo- controlled, trial with internet-based cognitive behavior therapy and sertraline or... | ||
| Medical condition: Prosepctive randomized two armed study to evaluate moderate depression during pregnancy treated with interbnetbased CBT and sertarline or placebo and longterm outcome in the children.Secondary obj... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: SE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-000586-19 | Sponsor Protocol Number: 307971 | Start Date*: 2005-07-25 |
| Sponsor Name:Bayer Schering Pharma AG | ||
| Full Title: Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC) | ||
| Medical condition: Non small cell lung cancer (NSCLC) stage IIIB or stage IV | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-001563-12 | Sponsor Protocol Number: 20142017 | Start Date*: 2015-02-16 |
| Sponsor Name:University Medical Center Groningen | ||
| Full Title: Efficacy of Single inhaler Maintenance And Reliever Therapy (SMART) with Spiromax® budesonide/formoterol versus fixed dose treatment with Diskus® fluticasone/salmeterol in COPD | ||
| Medical condition: Chronic obstructive pulmonary disease (COPD) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-005633-33 | Sponsor Protocol Number: 202000842 | Start Date*: 2021-06-02 |
| Sponsor Name:University Medical Center Groningen | ||
| Full Title: Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine | ||
| Medical condition: A depressive disorder | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-002324-41 | Sponsor Protocol Number: PH2/051 | Start Date*: 2006-11-30 | |||||||||||
| Sponsor Name:Cancer Research UK | |||||||||||||
| Full Title: A Cancer Research UK Randomised Multicentre Phase II Trial of the DNA-hypomethylating Agent, 5-Aza-2'-deoxycytidine(Decitabine) given intravenously in Combination with Carboplatin, versus Carboplat... | |||||||||||||
| Medical condition: Progressive, advanced ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004418-17 | Sponsor Protocol Number: I-BCT-1 | Start Date*: 2014-05-07 |
| Sponsor Name:Oslo University Hospital | ||
| Full Title: Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens. | ||
| Medical condition: breast cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-003003-31 | Sponsor Protocol Number: EORTC 26082 – 22081 | Start Date*: 2009-12-01 | |||||||||||
| Sponsor Name:EORTC Headquarters | |||||||||||||
| Full Title: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a ra... | |||||||||||||
| Medical condition: patients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoter | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003689-41 | Sponsor Protocol Number: CRAD001YGB11 | Start Date*: 2012-11-19 |
| Sponsor Name:Novartis Pharmaceuticals UK Ltd | ||
| Full Title: A Phase IV multicentre, open label study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with e... | ||
| Medical condition: oestrogen receptor positive breast cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-000601-11 | Sponsor Protocol Number: Soratace-1 | Start Date*: 2008-03-06 |
| Sponsor Name:Medizinische Universität Wien Univ. Klinik f. Innere Med. III, Abt. f. Gastroenterologie/Hepatologie | ||
| Full Title: SORATACE: Sorafenib (Nexavar®) as inhibitor of collateral tumor vessel growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a pilot trial to evaluate safety and ... | ||
| Medical condition: hepatocellular carcinoma patients undergoing transarterial chemoembolisation (TACE) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
